B
27.02
-0.22 (-0.81%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Bicycle Therapeutics plc | Bearish | Bearish |
Stockmoo Score
0.0
|
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fcpm Iii Services B.V. | 30 Jun 2024 | 2,122,892 |
| Fairmount Funds Management Llc | 30 Jun 2024 | 1,069,199 |
| Bnp Paribas Asset Management Holding S.A. | 30 Jun 2024 | 888,081 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 103.55%) | Buy |
| Median | 36.50 (35.09%) | |
| Low | 32.00 (JMP Securities, 18.43%) | Buy |
| Average | 40.00 (48.04%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 23.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Sep 2024 | 55.00 (103.55%) | Buy | 24.97 |
| JMP Securities | 16 Sep 2024 | 32.00 (18.43%) | Buy | 24.97 |
| Needham | 16 Sep 2024 | 38.00 (40.64%) | Buy | 24.97 |
| 09 Sep 2024 | 38.00 (40.64%) | Buy | 26.36 | |
| RBC Capital | 06 Sep 2024 | 35.00 (29.53%) | Buy | 20.54 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Sep 2024 | Announcement | Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024 |
| 03 Sep 2024 | Announcement | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 21 Aug 2024 | Announcement | Bicycle Therapeutics to Participate in Upcoming Investor Conferences |
| 06 Aug 2024 | Announcement | Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results |
| 01 Aug 2024 | Announcement | Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 22 Jul 2024 | Announcement | Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |